Giorgio Gallinella

Prof. Giorgio Gallinella

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 1994 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
KBKevin E. Brown
Kevin E. Brown
JHJonathan R. Hibbs
Jonathan R. Hibbs
GGGiorgio Gallinella
Giorgio Gallinella
SAStacie M. Anderson
Stacie M. Anderson
ELElton D. Lehman
Elton D. Lehman
NYNeal S. Young
Neal S. Young
The presence of a specific cellular receptor is thought to be necessary for susceptibility to viral infection. The erythrocyte P antigen is the cellular receptor for parvovirus B19. We hypothesized that the rare persons with the p phenotype, whose erythrocytes do not have this receptor, would be naturally resistant to B19 infection, which causes erythema infectiosum.

1 January 2014 in Blood Reviews
Verified
Journal Article
Closed access
DTDimitris A. Tsitsikas
Dimitris A. Tsitsikas
GGGiorgio Gallinella
Giorgio Gallinella
SPSneha Patel
Sneha Patel
HSHenry Seligman
Henry Seligman
PGPaul Greaves
Paul Greaves
RARoger J. Amos
Roger J. Amos

1 September 2007 in Gynecologic Oncology
Verified
Journal Article
Closed access
MCMonica Cricca
Monica Cricca
AMAntonio Maria Morselli‐Labate
Antonio Maria Morselli‐Labate
SVSimona Venturoli
Simona Venturoli
SASimone Ambretti
Simone Ambretti
GGGiovanna Angela Gentilomi
Giovanna Angela Gentilomi
MZMarialuisa Zerbini
Marialuisa Zerbini

1 November 1995 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MMM. Musiani
M. Musiani
MZM. Zerbini
M. Zerbini
GGG. Gentilomi
G. Gentilomi
MPM. Plazzi
M. Plazzi
GGGiorgio Gallinella
Giorgio Gallinella
SVS. Venturoli
S. Venturoli
The clearance of B19 parvovirus from peripheral blood was followed after acute infection to determine how long the virus is present in blood, even at low titer. The presence of B19 DNA in serum was investigated with dot blot hybridization during an epidemic. Fourteen patients positive for B19 DNA were followed for up to 1 year for its presence in samples taken monthly, using both dot blot hybridization and nested polymerase chain reaction (PCR). All patients examined showed medium to high viremic titers (detectable with hybridization assay) only at the beginning of observation; later the virus titer decreased and was detectable only by nested PCR. Of the 14 patients followed, 13 were positive for B19 DNA by nested PCR for 2-6 months; 1 patient showed a persistent infection associated with chronic arthritis and was positive for B19 DNA for 1 year without clearance of the virus.

18 July 2019 in Viruses
Verified
Journal Article
Open access
PDF file
EMElisabetta Manaresi
Elisabetta Manaresi
GGGiorgio Gallinella
Giorgio Gallinella
Parvovirus B19 (B19V) is a human pathogenic virus, responsible for an ample range of clinical manifestations. Infections are usually mild, self-limiting, and controlled by the development of a specific immune response, but in many cases clinical situations can be more complex and require therapy. Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy. The development of antiviral strategies against B19V should be considered of highest relevance for increasing the available options for more specific and effective therapeutic treatments. This field of research has been explored in recent years, registering some achievements as well as interesting future perspectives. In addition to immunoglobulins, some compounds have been shown to possess inhibitory activity against B19V. Hydroxyurea is an antiproliferative drug used in the treatment of sickle-cell disease that also possesses inhibitory activity against B19V. The nucleotide analogues Cidofovir and its lipid conjugate Brincidofovir are broad-range antivirals mostly active against dsDNA viruses, which showed an antiviral activity also against B19V. Newly synthesized coumarin derivatives offer possibilities for the development of molecules with antiviral activity. Identification of some flavonoid molecules, with direct inhibitory activity against the viral non-structural (NS) protein, indicates a possible line of development for direct antiviral agents. Continuing research in the field, leading to better knowledge of the viral lifecycle and a precise understanding of virus–cell interactions, will offer novel opportunities for developing more efficient, targeted antiviral agents, which can be translated into available therapeutic options.

1 October 2011 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
FBFrancesca Bonvicini
Francesca Bonvicini
CPChiara Puccetti
Chiara Puccetti
NSNunzio C. M. Salfi
Nunzio C. M. Salfi
BGBrunella Guerra
Brunella Guerra
GGGiorgio Gallinella
Giorgio Gallinella
MZMarialuisa Zerbini
Marialuisa Zerbini
Parvovirus B19 infection during pregnancy is a potential hazard to the fetus because of the virus' ability to infect fetal erythroid precursor cells and fetal tissues. Fetal complications range from transitory fetal anemia and nonimmune fetal hydrops to miscarriage and intrauterine fetal death. In the present study, 72 pregnancies complicated by parvovirus B19 infection were followed up: fetal and neonatal specimens were investigated by serological and/or virological assays to detect fetal/congenital infection, and fetuses and neonates were clinically evaluated to monitor pregnancy outcomes following maternal infection. Analysis of serological and virological maternal B19 markers of infection demonstrated that neither B19 IgM nor B19 DNA detected all maternal infections. IgM serology correctly diagnosed 94.1% of the B19 infections, while DNA testing correctly diagnosed 96.3%. The maximum sensitivity was achieved with the combined detection of both parameters. B19 vertical transmission was observed in 39% of the pregnancies, with an overall 10.2% rate of fetal deaths. The highest rates of congenital infections and B19-related fatal outcomes were observed when maternal infections occurred by the gestational week 20. B19 fetal hydrops occurred in 11.9% of the fetuses, and 28.6% resolved the hydrops with a normal neurodevelopment outcome at 1- to 5-year follow-up. In conclusion, maternal screening based on the concurrent analysis of B19 IgM and DNA should be encouraged to reliably diagnose maternal B19 infection and correctly manage pregnancies at risk.